Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06328179
NA

Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.

Sponsor: Huai'an First People's Hospital

View on ClinicalTrials.gov

Summary

This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA(Venetoclax with Homoharringtonine,Etoposide,Cytarabine)regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) with MLL gene abnormalities. This study includes the induction and consolidation phases of AML treatment.

Official title: Clinical Study Protocol for the Treatment of Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia With KMT2A Gene Abnormalities Using VHEA(Venetoclax With Homoharringtonine,Etoposide,Cytarabine)

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

34

Start Date

2022-05-24

Completion Date

2027-12-30

Last Updated

2024-03-25

Healthy Volunteers

No

Interventions

DRUG

Venetoclax 100 mg d1,200 mg d2,400 mg d3-14;

VHEA -Induction Phase Regimen/Consolidation therapy after remission

Locations (1)

The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University(Huai'an First People's Hospital)

Huai'an, Jiangsu, China